// App-Quantinova.ai

e21091 : Network meta-analysis (NMA) of immuno-oncology (IO) monotherapy as first-line (1L) treatments (txs) for advanced non-small cell lung cancer (NSCLC) with PD-L1 expression ≥50%.

Researchers

Presenter

  • Nicholas Freemantle

Principal Investigators

  • Yingxin Xu

  • Florence Wilson

  • Patricia Guyot

  • Chieh-I Chen

  • Sam Keeping

  • Gerasimos Konidaris

  • Keith Chan

  • Andreas Kuznik

  • Kokuvi Atsou

  • Emily Glowienka

  • Lisa Stow

  • Jean-Francois Pouliot

  • Giuseppe Gullo

  • Petra Rietschel

  • Naiyer A. Rizvi

Medical Centers

  • University College London, Institute of Clinical Trial and Methodology, London, United Kingdom

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Precision Xtract, Vancouver, BC, Canada

  • Canada.

  • Sanofi, Chilly-Mazarin, France

  • PRECISIONheor,Vancouver, BC,Canada

  • Sanofi, Reading, United Kingdom

  • Precision HEOR, Boston, MA

  • Sanofi, Cambridge, MA

  • Columbia University Medical Center, New York, NY

Locations

  • United Kingdom

  • United States

  • Canada

  • France

Companies

  • Regeneron Pharmaceut

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved